Youâre reading a free article with opinions that may differ from The Motley Foolâs Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.
RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partnerâs brokerage products, these are focused on the trading of readily releasable securities.
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) shares have been hammered since the company said it would post no sales or profit growth in the year ahead after all, but what is much more important for the long term is the reshaping taking place â and the new drugs coming down the line…
https://youtu.be/xaFY5fxXfwg